Key result
Pre-admission use of antiplatelet drugs was associated with substantially lower mortality in ICU patients (OR 0.20) and decreased odds of ICU admission for community-acquired pneumonia (OR 0.32).
Why the study?
Does prior antiplatelet therapy reduce mortality or ICU admission in critically ill patients and those with community-acquired pneumonia?
Population
615 patients consecutively admitted to an ICU and 224 patients consecutively admitted for community-acquired…
Comparison
Prior continuous medication with antiplatelet… vs Patients not receiving prior continuous…
Design
Editorial
Authors
Loading...
Prior use of antiplatelet drugs for secondary prevention may be associated with improved clinical outcomes, including reduced mortality and ICU admission, in patients with systemic inflammation or pneumonia.
Does prior antiplatelet therapy reduce mortality or ICU admission in critically ill patients and those with community-acquired pneumonia?
Odds Ratio: 0.2
Prior use of antiplatelet drugs for secondary prevention may be associated with improved clinical outcomes, including reduced mortality and ICU admission, in patients with systemic inflammation or pneumonia.
Winning et al. (2011) conducted a letter in Critical illness and community-acquired pneumonia (n=839). Antiplatelet drugs (acetylsalicylic acid, clopidogrel, thienopyridines) vs. No antiplatelet drugs was evaluated on Mortality (in ICU patients) (OR 0.20). Pre-admission use of antiplatelet drugs was associated with substantially lower mortality in ICU patients (OR 0.20) and decreased odds of ICU admission for community-acquired pneumonia (OR 0.32).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: